ARTV - Artiva Biotherapeutics Accounting Value per Share

Graphic logo of Artiva Biotherapeutics, Inc. (ARTV)

The calculated book value per share of Artiva Biotherapeutics, Inc. (ARTV) reflects current asset dynamics, with the metric standing at 7.18. Successes in clinical trials for allogeneic NK therapies and partnerships with pharma behemoths are driving the share price growth. Artiva Biotherapeutics, Inc. (ARTV) is recognized as a scientific leader in developing affordable anti-tumor drugs. Business development relies on tight operational integration with a key Asian partner within a strategic alliance.

ARTV (Artiva) Accounting Value per Share history from 07/20/2024 to 10/31/2026

Financial and market metric breakdowns for Artiva Biotherapeutics Inc. (ARTV)

- share price and expert price forecast:
Stock Quotes Artiva|ARTV - Analyst Forecast Prices
- market capitalization statistics:
Market Valuation Artiva Biotherapeutics, Inc.|ARTV - Total Company Value
- balance sheet net asset value indicators:
Book Value per Share Artiva Biotherapeutics|ARTV - Company Net Assets|Market Capitalization to Book Value Ratio artivabio.com|ARTV - Company Total Assets
- company total debt and liquidity indicators:
Debt to Equity Artiva Biotherapeutics, Inc.|ARTV - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Artiva|ARTV - Company Total Debt|Debts to Book Capitalization Artiva Biotherapeutics, Inc.|ARTV - Long-Term Debt|Company Short-Term Debt Artiva Biotherapeutics|Quick Liquidity Indicator artivabio.com
- net income and valuation multiples indicators:
ARTV - Final Profit
Initial company analysis:artivabio.com (ARTV)
Mass-produced product of Artiva Biotherapeutics Inc.

Artiva Biotherapeutics, Inc. (ARTV) focuses on costly NK-cell clinical trials, sustaining operations through external financing in the absence of current revenue. The average book value per share digitizes the remaining net assets after deducting all liabilities, reflecting the actual volume of capital available to shareholders, which allows this curve to assess the company's financial resilience amid negative cash flow.

Main competitors

ONC: Accounting Value per Share|Halozyme Corp - Book Price of a Share|RVMD (Revolution Medicines) - Accounting Value per Share|AAPG (ascentage.com) - Net Assets per Single Share|CGON (CG Oncology) - Book Value per Share|Accounting Value per Share UroGen Pharma Ltd (URGN)|Book Value per Share BCAX|Book Value per Share Personalis Genomics (PSNL)|Net Assets per Single Share Erasca, Inc. ERAS|DCTH: Equity per Share|Y-mAbs Therapeutics, Inc. - Book Value per Share|Aura Biosciences Inc (AURA) - Accounting Value per Share|CADL: Book Value per Share|Net Asset Value per Share Accuray, Inc. (ARAY)|Net Assets per Single Share SELLAS Life Sciences Group, Inc.|ACTU: Accounting Value of a Share|Accounting Value per Share CTOR (Citius Oncology)|HURA (tuhurabio.com) - Accounting Value of a Share|Book Value per Share TARA (Protara)|FATE - Accounting Value per Share|WHWK: Accounting Value per Share|TCRX - Book Value per Share|championsoncology.com (CSBR) - Net Assets per Single Share|XBiotech - Accounting Value of a Share|CVM (CEL-SCI Corp.) - Book Value per Share|Net Asset Value per Share OS Therapies, Inc. OSTX|Book Value per Share RADX|Book Value per Share adlainortye.com (ANL)|Net Assets per Single Share Veru VERU|Accounting Value of a Share TPST|XLO: Accounting Value per Share|Renovaro Inc. - Book Price of a Share|MURA: Book Value per Share|KAPA - Net Assets per Share|Accounting Value per Share OKUR|Net Assets per Single Share GDTC|Book Value per Share CRIS|Book Value per Share apollomicsinc.com (APLM)|Tharimmune, Inc. - Accounting Value per Share|Accounting Value of a Share ADVB|Genprex - Book Value per Share|CLDI: Net Assets per Single Share|SBFM: Book Value per Share|XBIO - Net Assets per Share|Net Assets per Single Share Salarius Pharmaceuticals|Net Asset Value per Share purple-biotech.com PPBT|Accounting Value per Share AONC (American Oncology Network)|Book Price of a Share BGNE|Book Value per Share CKPT (Checkpoint Therapeutics, Inc)|Accounting Value of a Share ELEV|iCAD Corp - Book Value per Share|Net Asset Value per Share Ikena Oncology, Inc.|Notable Labs (NTBL) - Net Assets per Single Share|Viracta Therapeutics, Inc. - Accounting Value of a Share|MOR (MorphoSys Corp) - Book Value per Share|Book Value per Share NAYA Biosciences Corp|Net Assets per Single Share Ascentage Pharma Group (AAPGV)